Insys Therapeutics, Inc. (NASDAQ:INSY) has received an average rating of “Hold” from the six analysts that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $13.33.

Several research analysts have weighed in on the company. Royal Bank of Canada set a $16.00 target price on Insys Therapeutics and gave the stock a “buy” rating in a report on Saturday, June 3rd. BidaskClub upgraded Insys Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Oppenheimer Holdings, Inc. reiterated a “hold” rating on shares of Insys Therapeutics in a report on Tuesday, July 4th. Jefferies Group LLC reduced their target price on Insys Therapeutics from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, April 4th. Finally, Piper Jaffray Companies lowered Insys Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the stock from $20.00 to $10.00 in a report on Wednesday, May 10th.

COPYRIGHT VIOLATION WARNING: This news story was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another domain, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this news story can be read at https://www.americanbankingnews.com/2017/07/10/insys-therapeutics-inc-nasdaqinsy-receives-average-rating-of-hold-from-analysts.html.

Shares of Insys Therapeutics (NASDAQ:INSY) opened at 13.12 on Monday. Insys Therapeutics has a 52 week low of $8.70 and a 52 week high of $19.96. The stock’s market capitalization is $946.28 million. The company has a 50-day moving average price of $12.62 and a 200 day moving average price of $11.03.

Insys Therapeutics (NASDAQ:INSY) last posted its earnings results on Tuesday, May 9th. The specialty pharmaceutical company reported ($0.09) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.10) by $0.01. The firm had revenue of $35.92 million for the quarter, compared to analyst estimates of $37.78 million. Insys Therapeutics had a negative return on equity of 0.97% and a negative net margin of 2.64%. The company’s revenue for the quarter was down 40.5% on a year-over-year basis. During the same period in the previous year, the company posted $0.11 earnings per share. Analysts forecast that Insys Therapeutics will post ($0.48) earnings per share for the current fiscal year.

In other news, Director Rohit Vishnoi purchased 4,000 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were bought at an average cost of $14.14 per share, for a total transaction of $56,560.00. Following the completion of the acquisition, the director now directly owns 4,000 shares in the company, valued at approximately $56,560. The purchase was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Saeed Motahari purchased 4,500 shares of the business’s stock in a transaction dated Tuesday, May 16th. The stock was purchased at an average price of $11.98 per share, for a total transaction of $53,910.00. Following the completion of the acquisition, the chief executive officer now owns 4,500 shares of the company’s stock, valued at $53,910. The disclosure for this purchase can be found here. Over the last quarter, insiders have acquired 21,900 shares of company stock worth $268,090. Corporate insiders own 67.90% of the company’s stock.

Several hedge funds have recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Insys Therapeutics during the fourth quarter worth approximately $3,408,000. Thrivent Financial For Lutherans purchased a new stake in shares of Insys Therapeutics during the first quarter worth approximately $1,058,000. Point72 Asset Management L.P. raised its stake in shares of Insys Therapeutics by 24.8% in the first quarter. Point72 Asset Management L.P. now owns 435,000 shares of the specialty pharmaceutical company’s stock worth $4,572,000 after buying an additional 86,373 shares during the period. First Trust Advisors LP raised its stake in shares of Insys Therapeutics by 105.3% in the first quarter. First Trust Advisors LP now owns 147,788 shares of the specialty pharmaceutical company’s stock worth $1,553,000 after buying an additional 75,817 shares during the period. Finally, Credit Agricole S A raised its stake in shares of Insys Therapeutics by 20.0% in the first quarter. Credit Agricole S A now owns 374,400 shares of the specialty pharmaceutical company’s stock worth $3,935,000 after buying an additional 62,400 shares during the period. Institutional investors own 28.12% of the company’s stock.

About Insys Therapeutics

Insys Therapeutics, Inc is a commercial-stage specialty pharmaceutical company. The Company develops and commercializes supportive care products. The Company’s product Subsys, is a sublingual fentanyl spray for breakthrough cancer pain (BTCP) in opioid-tolerant patients and a single-use product that delivers fentanyl, an opioid analgesic, for transmucosal absorption underneath the tongue.

Receive News & Ratings for Insys Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insys Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.